Isofol Medical
0.691 SEK -5.21%2 investors are following this company
Isofol Medical is a biotechnology company. The company conducts research and development in the fields of oncology. The company develops cancer drugs and drug candidates that are primarily intended for the treatment of colorectal cancer (CRC), one of the most common forms of cancer. In addition to the main activities, the companies also develop so-called rescue treatment after high-dose treatment with the cytotoxic methotrexate in osteosarcoma (bone cancer).
Revenue
720K
EBIT %
-5,788.89 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ISOFOL
Daily low / high price
0.68 / 0.728
SEK
Market cap
111.61M SEK
Turnover
202.51K SEK
Volume
290K
Latest videos
Financial calendar
General meeting
2024-05-08
Interim report
2024-05-08
Interim report
2024-08-21
Interim report
2024-11-12
Annual report
2025-02-19
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 10.1 % | 10.1 % |
Christian Haglund | 4.7 % | 4.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023
Kallelse till årsstämma den 8 maj 2024 i Isofol Medical AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools